Abstract
Purpose
Documentation of a wild-type (wt) KRAS gene in tumor has become mandatory for the prescription of anti-EGFR monoclonal antibodies in patients with colorectal cancer (CRC). Acquired KRAS mutations have seldom been reported in metastases from wt KRAS primary CRC. We report the first case of multiple KRAS mutations acquired during the metastatic phase of CRC, and retrospectively reviewed all patients with CRC, in whom KRAS was analyzed in at least two tumor samples from distinct lesions.
Methods
Genomic DNA purified from paraffin-embedded tissues was used after histological quantification of tumor tissue. The seven KRAS mutations located within codons 12 and 13 were screened using the allelic discrimination assay.
Results
A 35-year-old woman with CRC liver metastasis, resistant to all conventional cytotoxic agents, experienced for the first time significant tumor shrinkage while cetuximab was added, allowing hepatic resection. Further liver relapse occurred on cetuximab, but a new hepatic resection was attempted. No mutation in KRAS was detected in the primary colon tumor or in synchronous liver metastases. In contrast, in metachronous liver metastasis samples, two distinct mutations at codon 13 and 12 were detected. No acquired mutations were found in all the other 12 CRC cases with at least two serially performed KRAS analyses.
Conclusions
Our findings suggest that late switch in KRAS mutational status could occur more frequently than currently recognized and account for acquired resistance to anti-EGFR therapies. Prospective studies are warranted to better estimate the incidence of change in KRAS mutational status and assess their clinical relevance.
This is a preview of subscription content, log in via an institution to check access.
References
Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–997
Milano G, Etienne-Grimaldi MC, Dahan L et al (2008) Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19:2033–2038
Cappuzzo F, Varella-Garcia M, Finocchiaro G et al (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99:83–89
American Society of Clinical Oncology provisional clinical opinion (2009) Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096
Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136
Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379
Yang S, Farraye FA, Mack C, Posnik O, O’Brien MJ (2004) BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452–1459
Velho S, Moutinho C, Cirnes L et al (2008) BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8:255
Artale S, Sartore-Bianchi A, Veronese SM et al (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217–4219
Molinari F, Martin V, Saletti P et al (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100:1087–1094
Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622–2629
Santini D, Loupakis F, Vincenzi B et al (2008) High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13:1270–1275
Badalian G, Barbai T, Rásó E, Derecskei K, Szendrôi M, Tímár J (2007) Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 13:99–104
Kalikaki A, Koutsopoulos A, Trypaki M et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923–929
Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4:244–257
Sweeney C, Boucher KM, Samowitz WS et al (2009) Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer 48:1–9
Kimura K, Nagasaka T, Hoshizima N et al (2007) No duplicate K-RAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple K-RAS mutations. J Int Med Res 35:450–457
Losi L, Baisse B, Bouzourene H, Benhattar J (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26:916–922
Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J (2001) Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93:346–352
Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M, Hill RP (2009) Heterogeneity and power in clinical biomarker studies. J Clin Oncol 27:1517–1521
Holdhoff M, Schmidt K, Donehower R, Diaz LA Jr (2009) Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst 101:1284–1285
Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052–1061
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bouchahda, M., Karaboué, A., Saffroy, R. et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 66, 605–609 (2010). https://doi.org/10.1007/s00280-010-1298-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1298-9